Spinal Fluid DNA Analysis Could Aid Brain Tumor Diagnosis

For patients with unclear imaging, this test might eventually offer a way to detect tumors when traditional biopsies are too risky.

Updated on Oct. 26, 2026 in Cancer

Spinal Fluid DNA Analysis Could Aid Brain Tumor Diagnosis

Live Poll

Should medical researchers prioritize developing non-invasive tests over traditional tissue biopsy methods?

Mayo Clinic researchers are evaluating whether spinal fluid analysis can help diagnose brain tumors when standard imaging is unclear. The study tested the approach in 76 patients with suspected tumors or leptomeningeal disease to determine if tumor-related DNA could be detected.

Why it matters

When MRI scans are inconclusive or biopsies are too risky, clinicians lack clear diagnostic tools for certain brain abnormalities. This analysis aims to fill that diagnostic gap by identifying genetic markers directly in the fluid surrounding the brain and spinal cord.

This observational study evaluated 76 patients with suspected neurological conditions to assess the diagnostic utility of spinal fluid DNA. While 26% of the cohort showed detectable tumor-related DNA, the clinical sensitivity and diagnostic accuracy for all tumor types remain under investigation.

The players

Mayo Clinic

A Rochester-based academic medical center conducting advanced research on neuro-oncology and diagnostic biomarkers.

The details

To perform this analysis, doctors collect cerebrospinal fluid via a lumbar puncture and search for specific genetic mutations associated with tumor growth. This method is being explored because the blood-brain barrier often prevents tumor-derived DNA from entering the bloodstream, making traditional liquid biopsies less effective for brain cancers. Researchers are currently working to refine the technique to identify smaller amounts of DNA and are examining whether longitudinal tracking of biomarkers can reflect how a patient responds to treatment.

October 26, 2026: Findings were published.

Health Landscape

This research is part of a broader shift toward molecular diagnostics in neuro-oncology to overcome the limitations of standard imaging. It sits alongside ongoing efforts to improve the sensitivity of liquid biopsies, which currently struggle to bypass the protective blood-brain barrier.

If you are managing an uncertain brain abnormality, discuss with your neurologist whether advanced cerebrospinal fluid analysis is appropriate for your diagnostic plan. Keep in mind that current detection methods are still being refined and may not always yield sufficient usable DNA for a diagnosis.

The takeaway

Direct spinal fluid analysis may eventually serve as a vital tool for diagnosing complex brain tumors when standard biopsies are unsafe. Patients experiencing persistent, unexplained neurological symptoms should discuss the availability of specialized genetic testing with their care team.